Tetraphase Pharmaceuticals Now Covered by Analysts at Brean Capital (TTPH)
Brean Capital initiated coverage on shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) in a research note issued on Tuesday. The firm set a “buy” rating and a $23.00 price target on the stock. Brean Capital’s target price points to a potential upside of 99.13% from the company’s current price.
A number of other firms have also recently commented on TTPH. Analysts at TheStreet upgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 20th. Separately, analysts at Gabelli initiated coverage on shares of Tetraphase Pharmaceuticals in a research note on Friday, June 20th. They set a “buy” rating on the stock. Finally, analysts at Robert W. Baird initiated coverage on shares of Tetraphase Pharmaceuticals in a research note on Monday, June 16th. They set an “outperform” rating and a $21.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $18.75.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) traded down 1.73% on Tuesday, hitting $11.35. 210,413 shares of the company’s stock traded hands. Tetraphase Pharmaceuticals has a 1-year low of $7.30 and a 1-year high of $17.74. The stock’s 50-day moving average is $11.67 and its 200-day moving average is $12.38. The company’s market cap is $293.2 million.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its earnings results on Monday, May 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by $0.08. The company had revenue of $2.50 million for the quarter, compared to the consensus estimate of $2.97 million. On average, analysts predict that Tetraphase Pharmaceuticals will post $-2.11 earnings per share for the current fiscal year.
Tetraphase Pharmaceuticals, Inc, incorporated on July 7, 2006, is a clinical stage biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.